Gardasil News and Research

RSS

Gardasil is a vaccine that prevents the types of genital human papillomavirus (HPV) that cause most cases of cervical cancer and genital warts. The vaccine, Gardasil, is given in three shots over six-months. The vaccine is routinely recommended for 11 and 12 year old girls. It is also recommended for girls and women age 13 through 26 who have not yet been vaccinated or completed the vaccine series.

Gardasil safety questioned, CDC urged to back up statement with data

The National Vaccine Information Center (NVIC) is calling on the Centers for Disease Control (CDC) and Food and Drug Administration (FDA) to publicly release the study design, data and names of principal investigators involved in a statement this week maintaining that Gardasil vaccine is safe with no serious side effects.

26 Oct 2008

CDC officials did not know HPV vaccination recommendation for U.S. women also would affect prospective immigrants

Some of the CDC officials who supported a recommendation for young women in the U.S. to receive the human papillomavirus vaccine said they did not intend for it to lead to an immigration policy requiring young immigrant women to receive the vaccine, the Wall Street Journal reports (Jordan, Wall Street Journal, 10/1).

5 Oct 2008

Catholic school refuses to allow girls to have cervical cancer vaccine on school grounds

A Catholic school in Britain has refused to allow girls attending the school to have the cervical cancer vaccination on its premises.

25 Sep 2008

FDA approves expanded uses for Gardasil for vaginal and vulvar cancer caused by HPV

The U.S. Food and Drug Administration has announced the approval of the vaccine Gardasil for the prevention of vaginal and vulvar cancer caused by Human Papillomavirus (HPV) types 16 and 18 in girls and women ages 9 to 26.

14 Sep 2008

Refined Pap smear test more accurate

Italian researchers have found that a new method of testing for cervical cancer is more accurate than a pap smear and also picks up more dangerous lesions.

10 Sep 2008

Cervical cancer vaccine Gardasil can cause an allergic reaction

According to Australian researchers, the cervical cancer vaccine Gardasil can cause an allergic reaction in some girls.

8 Sep 2008

Pancreatitis link to Gardasil to be investigated by the TGA

Some Australian doctors are suggesting that a review of the cervical cancer vaccine Gardasil is called for after three patients contracted pancreatitis after having the vaccination.

18 Aug 2008

Advanced Cancer Therapeutics licenses technology to develop HPV vaccine

Advanced Cancer Therapeutics (ACT) has announced the signing of two new collaborative agreements that will advance development of the Company's novel human papillomavirus (HPV) vaccine program.

23 Jul 2008

Study looks at UK's controversial choice of HPV vaccine

The UK government may save up to £18.6 million a year by deciding to use the HPV vaccine Cervarix, given that it is equally effective as the more expensive Gardasil in preventing cervical abnormalities, according to a study published on BMJ.com.

19 Jul 2008

Gardasil reduces abnormal Pap test results

A significant drop in abnormal Pap test results happened after girls and women were given a vaccine to prevent cervical cancer, according to a researcher at the University of Alabama at Birmingham (UAB).

10 Mar 2008

New HPV vaccine 'nine-valent' under study

A new vaccine against nine of the most harmful strains of human papillomavirus is under study at the Medical College of Georgia.

19 Nov 2007

Review of controversy surrounding the human papillomavirus (HPV) vaccine

In an article appearing in the current issue of Clinical Pharmacology & Therapeutics, experts from the University of Pennsylvania Center for Bioethics and Johns Hopkins Berman Institute of Bioethics review the controversy surrounding the human papillomavirus (HPV) vaccine debate, and its effects on ethical and public health issues.

2 Nov 2007

HiFi DNA Tech files lawsuit against FDA

A lawsuit was filed Oct. 12 in U.S. District Court against the U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) related to reclassification of HPV DNA tests from class III to class II devices. The inaction by both agencies hinders introduction of new and affordable HPV testing to improve women’s health care.

15 Oct 2007

HPV infection and head and neck cancer

The human papillomavirus (HPV) has been implicated as a cause of cervical cancer in women, but there's another devastating form of cancer also linked to HPV infection - head and neck cancer - and almost no one is talking about it.

18 Sep 2007

Adolescents need to see their doctors more often to receive the HPV vaccine

Despite recommendations for annual preventive exams for adolescents, only 10 percent of teens have enough visits within 12 months to receive the recommended three shots needed for HPV vaccine. Ideally the three shots are delivered within six months, and only 1 percent of teens see their physicians that often.

5 Sep 2007

Oral sex the culprit in rising numbers of throat cancers

According to the latest figures on head and neck cancer, even though the rates for such cancers have dropped in recent years, throat cancer rates in the United States have not dropped.

28 Aug 2007

Worldwide distribution of cervical cancer virus is consistent with vaccine targets

The variety of human papilloma viruses that cause invasive cervical cancer cases worldwide are largely consistent across continents, according to a new study from the University of North Carolina at Chapel Hill.

3 Aug 2007

Benefits and risks of the new HPV vaccine aren't fully known

Media coverage of the recently introduced human papillomavirus (HPV) vaccine - including talk of state-mandated vaccination programs - has brought considerable attention, if not always clarity, to this issue.

2 Aug 2007

GSK's Cervarix receives positive opinion in Europe

GlaxoSmithKline has announced that its cervical cancer candidate vaccine received a positive opinion from the European Committee for Human Medicinal Products (CHMP) for the prevention of precancerous lesions (high grade cervical intraepithelial neoplasia - CIN grades 2 and 3) and cervical cancer causally related to human papillomavirus types 16 and 18.

19 Jul 2007

Requiring HPV vaccination for school-age girls for upcoming school year 'too soon,' researcher says

It is premature to require middle-school age girls to receive Merck's human papillomavirus vaccine Gardasil for the upcoming school year, Doug Lowy -- head of the National Cancer Institute's Laboratory of Cellular Oncology and one of the scientists responsible for the development of the vaccine -- said on Wednesday, CQ HealthBeat reports (Bartolf, CQ HealthBeat, 6/20).

22 Jun 2007